Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The searchable portal provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
Ramucirumab Paclitaxel Paclitaxel + placebo 2nd line advanced or metastatic gastric or EGJ adenocarcinoma Gastrointestinal Cancers Gastric or gastro-oesophageal junction cancer - Metastatic
2
Ramucirumab - Placebo 2nd line gastro-oesophageal or gastric cancer after cisplatin/5-FU Gastrointestinal Cancers Oesophageal Cancer - Metastatic
1
FOLFIRINOX - Gemcitabine 1st line advanced or metastatic. Good performance status Gastrointestinal Cancers Pancreatic cancer - Metastatic
5
Nab-paclitaxel Gemcitabine Gemcitabine 1st line advanced or metastatic. Good performance status (KPS>70%) Gastrointestinal Cancers Pancreatic cancer - Metastatic
2
Erlotinib Gemcitabine Gemcitabine + placebo 1st line advanced or metastatic Gastrointestinal Cancers Pancreatic cancer - Metastatic
1
Bevacizumab Combination chemotherapy Combination chemotherapy Recurrent, persistent or metastatic cervical cancer Gynaecological Malignancies Cervical Cancer - Metastatic
3
Bevacizumab Chemotherapy Paclitaxel or topotecan or liposomal doxorubicin Recurrent platinum-resistant ovarian cancer Gynaecological Malignancies Ovarian Cancer - Metastatic
4
Bevacizumab Paclitaxel + carboplatin Paclitaxel + carboplatin Early stage post-resection advanced ovarian or primary peritoneal ALL Gynaecological Malignancies Ovarian Cancer - Early
1
Bevacizumab Paclitaxel + carboplatin Paclitaxel + carboplatin Early stage post-resection advanced ovarian or primary peritoneal High risk Gynaecological Malignancies Ovarian Cancer - Early
3
Bevacizumab Gemcitabine + carboplatin Gemcitabine + carboplatin Recurrent platinum-sensitive ovarian cancer Gynaecological Malignancies Ovarian Cancer - Metastatic
3

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings